Intellectual property arrangements

Pharmaceutical patents – a targeted policy prescription

**redesign Extensions of term for Pharmaceutical patents**

The pharmaceutical industry relies on patents more than most. In addition to the standard patent 20 year term applying to all patent protection, pharmaceutical patents can qualify for a further five year extension of their term.

Extensions of term for pharmaceuticals were intended to attract investment in R&D and to provide an effective market life for pharmaceuticals more in line with other technologies. (The latter objective reflects the fact that pharmaceuticals must go through extensive regulatory approval processes that can be subject to delay.)

But extensions of term for pharmaceuticals have been ineffective in attracting investment. Australia represents only 2 per cent of the global pharmaceutical market and a meagre 0.3 per cent of global pharmaceutical R&D. And rather than focussing on delay caused by the regulator, extensions are calculated in a way that compensates firms for being slow to introduce drugs to the Australian market.

Not only have extensions of term been ineffective in encouraging pharmaceutical R&D, they cost the Australian Government and consumers over a quarter of a billion dollars each year.

Australia is bound, under its international obligations, to offer some adjustment of patent term for pharmaceuticals. But even within these constraints, there is scope to take a more sophisticated approach. Extending protection for pharmaceuticals should only occur where there have been *unreasonable* delays caused by the Therapeutic Goods Administration.

**DATA Protection drawbacks**

In addition to the patent protection afforded to pharmaceuticals, the data submitted in support of regulatory approval processes are also protected for a period of five years. Manufacturers of generic pharmaceuticals seeking to enter the market during the period of data exclusivity must independently test and prove that their pharmaceuticals are safe.

While data protection arrangements are intended to protect the investment in the test data, some in the industry see patent protection as inadequate and regard data protection as an ‘insurance policy’.

Not only is there a lack of evidence that patents are not doing the job, using data protection in their place has drawbacks. Data protection does not have the checks and balances that apply to patents and locks up valuable information.

[MORE]

Rather than restrict the availability of data, there is a case for making data more widely available. Allowing researchers access to test data could provide substantial public health benefits, while avoiding the substantial costs (and ethical concerns) of rehashing pre–existing trials. Efforts to unlock test data are best pursued through international cooperation.

**STRATEGIC (MIS)BEHAVIOUR — EVERGREENING AND PAY–FOR–DELAY**

Pharmaceutical patents are valuable assets. The ability of companies to leverage their intellectual property rights to forestall entry by generics has a direct and significant impact on their profitability. Evidence from Australia and overseas suggests that firms use a range of strategies to extend the (protected) commercial life of their products. Two strategies that firms can employ are so–called evergreening and pay–for–delay.

Evergreening is where a patent holder seeks multiple patents that cover different aspects of the same product. Some of these patents relate to genuine improvements that increase consumer wellbeing (such as significantly reducing side effects). But some improvements may only involve slightly different chemical combinations or production processes, with no appreciable difference to end users.

While it is difficult to differentiate strategic behaviour from genuine innovation, follow–on patenting is common. An analysis of the 15 costliest drugs under the Pharmaceutical Benefits Scheme found that the number of patents associated with each drug varied between 22 and 121 per drug.

To the extent that evergreening occurs, the Commission’s broader recommendation to raise the inventive step for patents, should directly address the problematic behaviours.

Pay–for–delay is where patent holders pay generic manufacturers to keep their products off the market for longer. By delaying price reductions for pharmaceuticals (that come with the availability of generics), these practices harm taxpayers and consumers.

Pay–for–delay settlements are well known within the United States and European Union. To date, there is scant evidence of such agreements in Australia — although this may in part be due to the difficulty of detecting suspect transactions, and assigning anticompetitive intent to them. Australia should follow overseas initiatives and introduce monitoring arrangements to detect pay–for–delay agreements.

[MORE]

**Do not delete this RETURN as it gives space between the table and what precedes it.**

|  |
| --- |
| Want to know more about what the Commission said on pharmaceuticals? |
|

|  |  |
| --- | --- |
| Issue | For more details and the Commission’s recommendation |
| Extensions of term | Pages 261‑271, draft recommendation 9.1 |
| Manufacture for export | Pages 271‑273, draft recommendation 9.2 |
| Protection for test data | Pages 274‑280, draft recommendation 9.3 |
| Strategic behaviour: evergreening | Pages 281‑284, draft recommendation 6.1 |
| Strategic behaviour: pay-for-delay | Pages 285‑289, draft recommendation 9.4, information request 9.1 |
| Data collection for policy analysis | Pages 289‑292, draft recommendation 9.5 |

 |
|  |
| **Do not delete this ROW as it gives space between the table and what follows it.** |

**Do not delete this RETURN as it gives space between the table and what precedes it.**

|  |
| --- |
| Having your say |
| The Productivity Commission is keen to hear your feedback on this draft report. You are welcome to make a written submission to the Commission, preferably in electronic format, by **3 June 2016**. More information on making a submission can be found on the inquiry website at <http://www.pc.gov.au/inquiries/current/intellectual-property/make-submission>Public hearings will be held in mid June 2016 — likely locations are Canberra, Melbourne and Sydney (to be determined by participant demand). Information on hearing dates and venues will be available on the inquiry website <http://www.pc.gov.au/inquiries/current/intellectual-property#draft>.The final report will be provided to the Australian Government on 18 August 2016. |
|  |
| **Do not delete this ROW as it gives space between the box and what follows it.** |

[END]